Halper Sadeh LLC Investigates Edwards Lifesciences for Potential Fiduciary Breaches
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 12 2026
0mins
Should l Buy EW?
Source: Globenewswire
- Investigation Context: Halper Sadeh LLC is investigating whether certain officers and directors of Edwards Lifesciences Corporation (NYSE: EW) breached their fiduciary duties to shareholders, which could impact corporate governance and shareholder rights.
- Shareholder Rights Protection: Long-term shareholders of Edwards may have the opportunity to seek corporate governance reforms, return of funds, or court-approved financial incentives, directly affecting investment returns and company transparency.
- Legal Fee Arrangement: The firm will handle the case on a contingent fee basis, meaning shareholders will not be responsible for out-of-pocket legal fees or expenses, reducing the financial risk of participation and encouraging more shareholders to get involved.
- Importance of Participation: Shareholder involvement can improve the company's policies, practices, and oversight mechanisms, thereby enhancing transparency and management effectiveness, ultimately contributing to increased shareholder value.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy EW?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on EW
Wall Street analysts forecast EW stock price to rise
24 Analyst Rating
16 Buy
8 Hold
0 Sell
Moderate Buy
Current: 81.260
Low
84.00
Averages
96.52
High
105.00
Current: 81.260
Low
84.00
Averages
96.52
High
105.00
About EW
Edwards Lifesciences Corporation is the global structural heart company. The Company partners with clinicians and researchers and invests in research and development to improve care for those impacted by structural heart disease. Its product categories include Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), and Surgical Structural Heart. It provides transcatheter heart valve replacement technologies designed for the minimally-invasive replacement of aortic heart valves. TAVR category includes the Edwards SAPIEN 3, the Edwards SAPIEN 3 Ultra and the Edwards SAPIEN 3 Ultra RESILIA systems. TMTT category includes the PASCAL Precision transcatheter repair system, EVOQUE tricuspid valve replacement system and Cardioband tricuspid valve reconstruction system. Its INSPIRIS RESILIA aortic valve, offers RESILIA tissue and VFit technology. It is managed in various geographical regions, such as United States, Europe, Japan and Rest of World.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Anteris Aims to Reshape $10B Heart Market with Innovative Valve
- Market Opportunity Identification: Anteris Technologies is developing a new TAVR valve through its DurAVR program to meet the needs of younger patients requiring heart valve replacements, with the market projected to reach $10 billion by 2028, indicating significant growth potential.
- Design Innovation: Unlike existing valves, DurAVR features a single-piece molded design combined with a balloon-expandable delivery system, aiming to provide superior hemodynamic performance and address the trade-off between ease of use and performance seen in traditional valves.
- Clinical Trial Progress: Anteris has treated over 130 patients in early studies, demonstrating favorable hemodynamic performance with low pressure gradients and minimal prosthesis-patient mismatch, with the next phase being the PARADIGM pivotal trial enrolling around 1,000 patients for comparative analysis.
- Strategic Investment Support: In early 2026, Anteris completed a $320 million capital raise, including a $90 million strategic investment from Medtronic, validating the technology and market opportunity despite Medtronic being a competitor.
See More
Market Watch: Corporate Dynamics and Analysis
- Nike's Disappointing Performance: Despite beating revenue and earnings expectations, Nike issued weak guidance due to inventory issues and a slowdown in North American growth, prompting downgrades from Goldman, JPMorgan, and Bank of America, reflecting market concerns about its future performance.
- RH's Poor Earnings Report: Luxury home furnishings maker RH fell short on key metrics in its fourth quarter, and its current quarter guidance was also weak, impacted by tariffs and a sluggish housing market, leading to an 18% drop in shares, although its full-year cash flow guidance improved, the overall outlook remains bleak.
- Arm's Price Target Increase: Wells Fargo raised Arm's price target from $165 to $175, with analysts optimistic about Arm's entry into the data center CPU market with its first in-house silicon offering, reiterating a buy rating, indicating strong market confidence in its competition against Intel and AMD.
- Boeing Stock Rating Upgrade: Wells Fargo upgraded Boeing's stock to buy with a price target of $250, implying over 25% upside from yesterday's close, as analysts favor Boeing's free cash flow recovery and overall turnaround under CEO Kelly Ortberg, suggesting potential returns for investors.
See More
Analyst Opinions Impact Edwards Lifesciences Ranking
- Analyst Ranking Mechanism: The ranking is formed by averaging analyst opinions for each component, thereby ranking 500 components and reflecting market perceptions of various companies.
- Stock Performance Review: Year-to-date, Edwards Lifesciences' stock price has decreased by approximately 6.2%, indicating a cautious market sentiment regarding its future performance, which may affect investor confidence.
- Diversity of Market Opinions: While the ranking provides an overall market perspective, the author emphasizes that these views do not necessarily reflect those of Nasdaq, showcasing the diversity and complexity of analyst opinions.
- Impact on Investor Decisions: Analyst opinions and rankings can influence investor decisions, particularly in light of the stock price decline, prompting investors to reassess their investment strategies in Edwards Lifesciences.
See More
Stock Performance Comparison: EW vs. DRI
- Stock Performance Analysis: EW is currently trading up approximately 0.7%, indicating a relatively stable market performance amidst overall volatility, suggesting cautious optimism from investors regarding its future growth.
- DRI Stock Movement: DRI is up about 1.3% midday Monday, outperforming EW, which may reflect stronger market confidence in DRI or positive impacts from its recent business strategies.
- Market Comparison: The three-month price history chart comparing EW and DRI provides critical decision-making insights for investors, particularly when considering potential investments.
- Investor Sentiment: While both stocks are up, DRI's stronger performance may attract more investor attention, potentially influencing future capital inflows and market dynamics.
See More
EVOQUE System Shows Lower Mortality in TRISCEND II Trial Data
- Clinical Trial Results: At the American College of Cardiology Annual Scientific Session, Edwards Lifesciences announced TRISCEND II trial data showing that the EVOQUE transcatheter tricuspid valve replacement system significantly lowers all-cause mortality, particularly when accounting for patient crossover, highlighting the efficacy and necessity of this technology.
- Symptom Improvement: The trial also demonstrated that the EVOQUE system nearly eliminates tricuspid regurgitation, improves health status and quality of life for patients, indicating the treatment's potential in alleviating severe symptoms and addressing the urgent need for effective therapies.
- Safety Analysis: The EVOQUE system did not introduce additional device-related risks during clinical application, and data from over 1,000 patients in the STS/ACC TVT Registry consistently show a positive safety profile and effectiveness, further enhancing its prospects in structural heart disease treatment.
- Market Outlook: The EVOQUE system is approved in both the US and Europe, and Edwards Lifesciences is committed to developing innovative solutions to meet the needs of patients with structural heart disease, which is expected to drive the company's continued growth in cardiac treatment.
See More
Investment Opportunities in Asian Small Caps
- Market Dynamics: Amid geopolitical tensions and fluctuating energy prices, Asian markets have shown resilience, with the S&P MidCap 400 and Russell 2000 indices remaining stable, attracting investor interest in small-cap stocks as potential value plays.
- Small Cap Appeal: Insider buying has become a crucial indicator for identifying stocks with strong fundamentals, particularly in the current market environment, reflecting confidence in future company performance and potentially offering good entry points for investors.
- Company Financial Performance: For instance, ARB announced a fully franked dividend of A$0.34 per share for 2025, despite a slight revenue dip to A$362.21 million, insider purchases in Q1 2026 indicate confidence in future growth, with an expected annual growth rate of 9.52%.
- Industry Outlook: Companies like MREIT and China Lilang also demonstrate strong financial performance, with MREIT reporting annual sales of PHP 4.3 billion; despite a decline in earnings per share, ongoing insider buying signals confidence in the company's future, with projected annual growth exceeding 9%.
See More
Anteris Aims to Reshape $10B Heart Market with Innovative Valve
- Market Opportunity Identification: Anteris Technologies is developing a new TAVR valve through its DurAVR program to meet the needs of younger patients requiring heart valve replacements, with the market projected to reach $10 billion by 2028, indicating significant growth potential.
- Design Innovation: Unlike existing valves, DurAVR features a single-piece molded design combined with a balloon-expandable delivery system, aiming to provide superior hemodynamic performance and address the trade-off between ease of use and performance seen in traditional valves.
- Clinical Trial Progress: Anteris has treated over 130 patients in early studies, demonstrating favorable hemodynamic performance with low pressure gradients and minimal prosthesis-patient mismatch, with the next phase being the PARADIGM pivotal trial enrolling around 1,000 patients for comparative analysis.
- Strategic Investment Support: In early 2026, Anteris completed a $320 million capital raise, including a $90 million strategic investment from Medtronic, validating the technology and market opportunity despite Medtronic being a competitor.
See More
Market Watch: Corporate Dynamics and Analysis
- Nike's Disappointing Performance: Despite beating revenue and earnings expectations, Nike issued weak guidance due to inventory issues and a slowdown in North American growth, prompting downgrades from Goldman, JPMorgan, and Bank of America, reflecting market concerns about its future performance.
- RH's Poor Earnings Report: Luxury home furnishings maker RH fell short on key metrics in its fourth quarter, and its current quarter guidance was also weak, impacted by tariffs and a sluggish housing market, leading to an 18% drop in shares, although its full-year cash flow guidance improved, the overall outlook remains bleak.
- Arm's Price Target Increase: Wells Fargo raised Arm's price target from $165 to $175, with analysts optimistic about Arm's entry into the data center CPU market with its first in-house silicon offering, reiterating a buy rating, indicating strong market confidence in its competition against Intel and AMD.
- Boeing Stock Rating Upgrade: Wells Fargo upgraded Boeing's stock to buy with a price target of $250, implying over 25% upside from yesterday's close, as analysts favor Boeing's free cash flow recovery and overall turnaround under CEO Kelly Ortberg, suggesting potential returns for investors.
See More
Analyst Opinions Impact Edwards Lifesciences Ranking
- Analyst Ranking Mechanism: The ranking is formed by averaging analyst opinions for each component, thereby ranking 500 components and reflecting market perceptions of various companies.
- Stock Performance Review: Year-to-date, Edwards Lifesciences' stock price has decreased by approximately 6.2%, indicating a cautious market sentiment regarding its future performance, which may affect investor confidence.
- Diversity of Market Opinions: While the ranking provides an overall market perspective, the author emphasizes that these views do not necessarily reflect those of Nasdaq, showcasing the diversity and complexity of analyst opinions.
- Impact on Investor Decisions: Analyst opinions and rankings can influence investor decisions, particularly in light of the stock price decline, prompting investors to reassess their investment strategies in Edwards Lifesciences.
See More
Stock Performance Comparison: EW vs. DRI
- Stock Performance Analysis: EW is currently trading up approximately 0.7%, indicating a relatively stable market performance amidst overall volatility, suggesting cautious optimism from investors regarding its future growth.
- DRI Stock Movement: DRI is up about 1.3% midday Monday, outperforming EW, which may reflect stronger market confidence in DRI or positive impacts from its recent business strategies.
- Market Comparison: The three-month price history chart comparing EW and DRI provides critical decision-making insights for investors, particularly when considering potential investments.
- Investor Sentiment: While both stocks are up, DRI's stronger performance may attract more investor attention, potentially influencing future capital inflows and market dynamics.
See More
EVOQUE System Shows Lower Mortality in TRISCEND II Trial Data
- Clinical Trial Results: At the American College of Cardiology Annual Scientific Session, Edwards Lifesciences announced TRISCEND II trial data showing that the EVOQUE transcatheter tricuspid valve replacement system significantly lowers all-cause mortality, particularly when accounting for patient crossover, highlighting the efficacy and necessity of this technology.
- Symptom Improvement: The trial also demonstrated that the EVOQUE system nearly eliminates tricuspid regurgitation, improves health status and quality of life for patients, indicating the treatment's potential in alleviating severe symptoms and addressing the urgent need for effective therapies.
- Safety Analysis: The EVOQUE system did not introduce additional device-related risks during clinical application, and data from over 1,000 patients in the STS/ACC TVT Registry consistently show a positive safety profile and effectiveness, further enhancing its prospects in structural heart disease treatment.
- Market Outlook: The EVOQUE system is approved in both the US and Europe, and Edwards Lifesciences is committed to developing innovative solutions to meet the needs of patients with structural heart disease, which is expected to drive the company's continued growth in cardiac treatment.
See More
Investment Opportunities in Asian Small Caps
- Market Dynamics: Amid geopolitical tensions and fluctuating energy prices, Asian markets have shown resilience, with the S&P MidCap 400 and Russell 2000 indices remaining stable, attracting investor interest in small-cap stocks as potential value plays.
- Small Cap Appeal: Insider buying has become a crucial indicator for identifying stocks with strong fundamentals, particularly in the current market environment, reflecting confidence in future company performance and potentially offering good entry points for investors.
- Company Financial Performance: For instance, ARB announced a fully franked dividend of A$0.34 per share for 2025, despite a slight revenue dip to A$362.21 million, insider purchases in Q1 2026 indicate confidence in future growth, with an expected annual growth rate of 9.52%.
- Industry Outlook: Companies like MREIT and China Lilang also demonstrate strong financial performance, with MREIT reporting annual sales of PHP 4.3 billion; despite a decline in earnings per share, ongoing insider buying signals confidence in the company's future, with projected annual growth exceeding 9%.
See More
